Beam sells opt-in rights to Eli Lilly for up to $600M


About two weeks after announcing a restructuring and layoffs, this Cambridge gene-editing startup is selling off some of its opt-in rights.

Previous Janney taps company veteran as new president
Next Auction of historic Georgetown home where Jackie Kennedy lived after JFK's assassination gavels close at $15M